Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.
Alberto A ChiapporiBenjamin C CreelanTawee TanvetyanonJhanelle E GrayEric B HauraRam ThapaMargaret L BarlowZhihua ChenDung Tsa ChenAmer A BegTheresa A BoyleJulio CastroLiza MorganErick J MorrisMehreteab AregayFelipe K HurtadoLuigi ManentiScott AntoniaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Taminadenant, with and without spartalizumab, was well tolerated in patients with advanced NSCLC. The maximum tolerated dose of taminadenant alone was 480 mg twice a day, and 240 mg twice a day plus spartalizumab. Efficacy was neither a primary or secondary endpoint; however, some clinical benefit was noted regardless of prior immunotherapy or programmed cell death ligand-1 status.